with Kyprolis. What kind of discontinuation rates are you seeing in patients treated?
second question, just a reminder on the ASPIRE study. Is the Revlimid in the control arm being dosed to progression, i.e., maintenance? Or is it dosed for just an induction period?
It's probably too early to talk about discontinuation for Kyprolis. Helen's nodding her head, yes. So I think that's the answer on that one. And then have -- Barb, comment a little bit, if you can, about the dosing for Revlimid and ASPIRE.
I'll quickly say that we are dosing the Revlimid to progression.